APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/511,490	10/14/2005	Pavel V. Bondarenko	1004US/PCT	4633

44064   7590   06/11/2009
THERMO FINNIGAN LLC
355 RIVER OAKS PARKWAY
SAN JOSE, CA 95134

EXAMINER
XU, XIAOYUN

ART UNIT	PAPER NUMBER
1797	

MAIL DATE	DELIVERY MODE
06/11/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE _3_ MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) ☒ Responsive to communication(s) filed on _21 April 2009_.

2a) ☒ This action is **FINAL**.   2b) ☐ This action is non-final.

3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) ☒ Claim(s) _44-61,63-68,71,73 and 74_ is/are pending in the application.

    4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) ☐ Claim(s) _____ is/are allowed.

6) ☒ Claim(s) _44-61, 63-68, 71 and 73-74_ is/are rejected.

7) ☐ Claim(s) _____ is/are objected to.

8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) ☐ The specification is objected to by the Examiner.

10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.

    Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

    Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

    a) ☐ All   b) ☐ Some *   c) ☐ None of:

      1. ☐ Certified copies of the priority documents have been received.

      2. ☐ Certified copies of the priority documents have been received in Application No. _____.

      3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

    * See the attached detailed Office action for a list of the certified copies not received.

DETAILED ACTION

1.   The amendment filed 04/21/2009 has been entered and fully considered. Claims 62, 69, 70 and 72 are canceled. Claims 44-61, 63-68, 71 and 73-74 are pending.

Response to Amendment

2.   In response to amendment, the examiner maintains rejection over the prior art established in the previous Office action.

Claim Rejections - 35 USC § 103

3.   The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

4.   **Claims 44-61, 63-68, 71 and 73-74** are rejected under 35 U.S.C. 103(a) as being unpatentable over Gygi et al. (Nature Biotechnology, 1999, IDS) (Gygi).

In regard to Claim 44, Gygi teaches a method for quantifying peptides in a peptide mixture. The method comprises

receiving a first peptide mixture containing a plurality of peptides (tagged with light form of reagent) (see page 994, right col. 3rd paragraph);

separating the plurality of peptide of the first mixture over a period of time (see page 994, right col. 3rd paragraph);

mass-to-charge analyzing the separated peptides of the first peptide mixture at a particular time in the period of time (see page 994, right col. 3rd paragraph, page 995 and Figure 2);

calculating an abundance of the mass analyzed peptides of the first peptide mixture (see page 994, right col. 3rd paragraph, page 995 and Figure 2);

calculating a relative quantity for mass analyzed peptides of the first peptide mixture by comparing the calculated abundance of mass analyzed peptides of the first peptide mixture (tagged with light form of reagent) with an abundance of peptides in a reference sample (tagged with heavy form of reagent) (see page 994, right col. 3rd paragraph).

Gygi does not teach that the reference sample is external to the first peptide mixture. Applicant is advised that the rationale to support a conclusion that the claim would have been obvious is that all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results to one of ordinary skill in the art. (see KSR, 550 U.S. at ___, 82 USPQ2d at 1395) (see MPEP 2143). In that regard, using internal or external reference in mass spectrometry is well known in the art. When the mass-to-charge signal of reference does not overlap with the signal of the target sample, the reference can be used as an internal and/or an external reference. When the mass-to-charge signal of the reference overlaps with the signal of the target sample, then the reference can only be used as an external reference. Therefore, the choice of internal and external reference is an obvious variation in mass spectrometry analysis. In Gygi's case, the signal of the reference does not overlap with the target sample; therefore, either internal or external reference can be used. Gygi choose to use internal reference so that the reference is measured under the exactly the same condition as the target sample. At time of the invention, it would have been obvious for a person of ordinary skill in the art to decide whether an internal reference or an external reference is more suitable for the mass spectrometry analysis.

In regard to Claim 45, Gygi teaches digesting a first polypeptide sample to generate the first peptide mixture (see page 994, right col. 3rd paragraph).

In regard to Claim 46, Gygi teaches preparing the reference sample by digesting a second polypeptide sample (see page 994, right col. 3rd paragraph);

separating peptides from the digested second polypeptide sample (see page 994, right col. 3rd paragraph);

mass analyzing the separated peptide from the digested second polypeptide sample (see page 994, right col. 3rd paragraph, page 995, left col. 1st paragraph); and

calculating an abundance of mass analyzed peptides from the second polypeptide sample (see page 994, right col. 3rd paragraph);

calculating relative quantity for the mass analyzed peptides of the first peptide mixture by comparing the calculated abundance of mass analyzed peptides of the first peptide mixture (tagged with light form of reagent) with the calculated abundance of corresponding mass analyzed peptide from the second polypeptide sample (tagged with heavy form of reagent) (see page 994, right col. 3rd paragraph).

In regard to Claims 47 and 48, Gygi teaches separating peptides by liquid chromatography, isolating a liquid chromatography eluent at the particular time and mass analysis the isolated eluent (LC-MS/MS) (see page 994, right col. 3rd paragraph).

In regard to Claims 49-51, Gygi teaches fragmenting an ion derived from a peptide of separated peptides and mass analyzing fragments of the ion (LC-MS/MS) and identifying peptides in the first sample by searching a sequence database based on mass analysis information for the fragments (see page 995).

In regard to Claim 52, Gygi teaches reconstructing a chromatogram peak for a peptide based on mass analysis information for the peptide (see page 996 and Figure 3).

In regard to Claim 53, Gygi teaches calculating an abundance of a peptide based on a reconstructed chromatogram peak area for the peptide (see page 996 right col.)

In regard to Claim 54, Gygi does not specifically teach using only chromatogram peaks located within a threshold distance in the reconstructed chromatogram of the particular time. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). In that regard, it is well know in chromatography that each eluent peak has a retention time that corresponds to its peak intensity. Therefore, it would have been obvious to a person of ordinary skill in the art to run MS analysis at the retention time that is as close to the peak retention time as possible in order to obtain the highest intensity of MS chromatogram. The optimum threshold distance from the peak retention time can be obtained by routine experimentation.

In regard to Claim 55, Gygi teaches calculating a relative quantity of mass analyzed peptides by comparing an abundance calculated by reconstructing a

chromatogram peak area for a peptide of the first peptide mixture (tagged with light form
of reagent) with an abundance calculated by reconstructing a chromatogram peak area
for a peptide in the reference sample (tagged with heavy form of reagent) (see page
996, left co. 3rd paragraph, right col. and Figure 3).

In regard to Claims 56 and 57, Gygi teaches normalizing the calculated
abundance of mass analyzed peptides of the first peptide mixture (tagged with the light
form of the reagent) based on an internal standard (tagged with the heavy form of the
reagent) that is added to the first polypeptide sample (see page 996, Table 1).

In regard to Claim 58, Gygi does not teach normalizing the calculated abundance
based on an external standard. As has been discussed with respect to claim 1 above,
external standard is an obvious variation of internal standard. At time of the invention, it
would have been obvious for a person of ordinary skill in the art to decide whether an
internal reference or an external reference is more suitable for normalization analysis.

In regard to Claim 59, Gygi teaches identifying a plurality of peptides of the first
peptide mixture based on the MS/MS analysis and combining the results generated
from MS and MS/MS analysis to calculate (determine) a relative quantity for each of the
identified peptides (see page 995).

In regard to Claim 60, Gygi teaches that the relative quantification is determined
by the ratio of reconstructed chromatogram peak area of the peptide pairs (see page
995). In other words, the relative quantification is determined by calculating the
correction factor based on reconstructed chromatogram peak area of the peptide. Gygi
does not specifically teach calculating a single correction factor for a set of peptides in
the first peptide mixture. However, when correction factors are calculated for each of the
peptides in the first peptide mixture, a single correction factor for the peptide set in the
first peptide mixture can be calculated in a similar way based on a single reference. It
would have been obvious to a person of ordinary skill in the art to calculate a single
correction factor for the peptide set in the first peptide mixture based on a single
reference in a same way as taught by Gygi.

In regard to Claim 61, Gygi teaches mass-to-charge analyzing and calculating an
abundance for arbitrary peptides of the first peptide mixture (see page 995).

In regard to Claim 63, Gygi teaches an apparatus for quantifying peptides in a peptide mixture. The apparatus comprises

means for receiving a first peptide mixture containing a plurality of peptides (tagged with isotopically light form of reagent) (see page 994, right col. 3rd paragraph);

means for separating the plurality of peptides of the first peptide mixture over a period of time (see page 994, right col. 3rd paragraph);

means for mass analyzing the separated peptides of the first peptide mixture at a particular time in the period of time (see page 994, right col. 3rd paragraph, page 995);

means for calculating an abundance of the mass analyzed peptides of the first peptide mixture (see page 994, right col. 3rd paragraph, page 995);

means for calculating a relative quantity for mass analyzed peptides of the first peptide mixture by comparing the calculated abundance of the mass analyzed peptides of the first peptide mixture (tagged with isotopically light form of reagent) with an abundance of peptides in a reference sample (tagged with isotopically heavy form of reagent) (see page 994, right col. 3rd paragraph, page 995);

Gygi does not teach that the reference sample is external to the first peptide mixture. Using internal or external reference in mass spectrometry is well known in the art. The choice of internal and external reference is an obvious variation in mass spectrometry analysis. At time of the invention, it would have been obvious for a person of ordinary skill in the art to decide whether an internal reference or an external reference is more suitable for the mass spectrometry analysis.

In regard to Claims 64 and 65, Gygi teaches apparatus that also receives one additional peptide mixture (tagged with isotopically heavy form of reagent) as reference sample (see page 994, right col. 3rd paragraph).

In regard to Claim 66, Gygi teaches that peptides are quantified by measuring the relative signal intensities for pairs of peptide ions of identical sequence in the first peptide mixture (tagged with the isotopically light form of the reagent) and the reference sample (tagged with isotopically heavy form of the reagent) (see page 994, right col. 3rd paragraph).

In regard to Claim 67, Gygi teaches mass-to-charge analyzing and calculating an abundance for arbitrary peptides of the first peptide mixture (see page 995, Figure 2 and 3).

In regard to Claim 68, Gygi teaches separating, mass-to-charge analyzing and calculating an abundance for peptides of the subject peptides (see page 994, right col. 3rd paragraph, page 995). Gygi's method requires at least one cysteinyl residue present in the peptide in order to be tagged with the isotope reagent. Therefore, Gygi does not teach handling peptides independent of a particular amino acids composition. However, using internal or external reference in mass spectrometry is well known in the art. When external reference is used, isotope tag reagent will not be needed and therefore, the presence of cysteinyl residue in the peptide will not be required. At time of the invention it would have been obvious for a person of ordinary skill in the art to use external reference sample in Gygi's apparatus to handle peptide that does not have cysteinyl residue.

In regard to Claim 71, Gygi discloses an apparatus for quantifying peptides in a first peptide mixture. The apparatus comprises digital circuitry configured to perform the following actions:

receiving separation information representing a separation of a plurality of peptides of a first peptide mixture over a period of time (see page 994, right col. 3rd paragraph);

receiving mass-to-charge analysis information for the separated peptides of the first peptide mixture at a particular time in the period of time (see page 994, right col. 3rd paragraph, page 995);

calculating an abundance of the mass analyzed peptides of the first peptide mixture (see page 994, right col. 3rd paragraph, page 995); and

calculating a relative quantity for the mass analyzed peptides of the first peptide mixture by comparing the calculated abundance of the mass analyzed peptides of the first peptide mixture with an abundance of the peptides in a reference sample, the reference sample being external to the first peptide mixture (see page 994, right col. 3rd paragraph, page 995);

Gygi does not teach that the reference sample is external to the first peptide mixture. Using internal or external reference in mass spectrometry is well known in the art. The choice of internal and external reference is an obvious variation in mass spectrometry analysis. At time of the invention, it would have been obvious for a person of ordinary skill in the art to decide whether an internal reference or an external reference is more suitable for the mass spectrometry analysis.

In regard to Claims 73 and 74, Gygi teaches a method and apparatus for quantifying peptides in a biological sample. Gygi does not specifically teach that the method and apparatus can also be used for quantifying compounds in a biological sample. The court has held that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim (see MPEP 7.37.09). In that regards, the processes and apparatus recited in the instant claims can be derived from Gygi's teaching by simply substituting peptide with the compound (see page 994, right col. 3rd paragraph, page 995). At the time of the invention it would have been obvious for a person of ordinary skill in the art to use Gygi's method and apparatus for quantifying compound in a biological sample.

Response to Arguments

5.   Applicant's arguments filed 04/21/2009 have been fully considered but they are not persuasive.

Applicants argue that Gygi teaches away from using external standard as reference sample to quantify analyte citing Aebersold et al. (US Patent 6,852,544, attached in the amendment) (Aebersold) as the supporting evidence. However, the Aebersold citation does not comment on using external standard as reference in the mass spectrometry analysis. Therefore, just because Aebersold teach using internal standard as reference sample in mass spectrometry analysis, does not imply that Aebersold teaches away from using external standard as reference sample.

Conclusion

6.   **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time
policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE
MONTHS from the mailing date of this action. In the event a first reply is filed within
TWO MONTHS of the mailing date of this final action and the advisory action is not
mailed until after the end of the THREE-MONTH shortened statutory period, then the
shortened statutory period will expire on the date the advisory action is mailed, and any
extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of
the advisory action. In no event, however, will the statutory period for reply expire later
than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the
examiner should be directed to ROBERT XU whose telephone number is (571)270-
5560. The examiner can normally be reached on Mon-Thur 7:30am-5:00pm, Fri
7:30am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's
supervisor, Vickie Kim can be reached on (571)272-0579. The fax phone number for
the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the
Patent Application Information Retrieval (PAIR) system. Status information for
published applications may be obtained from either Private PAIR or Public PAIR.
Status information for unpublished applications is available through Private PAIR only.
For more information about the PAIR system, see http://pair-direct.uspto.gov. Should
you have questions on access to the Private PAIR system, contact the Electronic
Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a
USPTO Customer Service Representative or access to the automated information
system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

6/10/2009   /Yelena G. Gakh/
                                                            Primary Examiner, Art Unit 1797
RX